ImmunoGen, Inc.
(NASDAQ : IMGN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. 1.32%697.332.6%$644.85m
MRNAModerna, Inc. -0.55%123.640.0%$634.51m
AMGNAmgen, Inc. -0.34%226.971.4%$624.69m
GILDGilead Sciences, Inc. -1.43%62.861.0%$494.49m
VRTXVertex Pharmaceuticals, Inc. -1.01%283.451.9%$355.83m
ILMNIllumina, Inc. -1.61%190.383.2%$291.37m
SNSSSunesis Pharmaceuticals, Inc. -5.81%4.050.7%$283.11m
BIIBBiogen, Inc. -1.42%197.781.8%$184.42m
SAVACassava Sciences, Inc. -18.00%41.870.0%$173.71m
BNTXBioNTech SE -1.27%128.350.0%$100.39m
NRBONeuroBo Pharmaceuticals, Inc. -6.44%15.540.0%$89.03m
NVAXNovavax, Inc. -6.42%21.0075.6%$85.66m
BMRNBioMarin Pharmaceutical, Inc. -0.09%84.844.2%$76.07m
EXASEXACT Sciences Corp. -2.74%33.4117.6%$71.49m
CRSPCRISPR Therapeutics AG -2.68%63.160.6%$69.53m

Company Profile

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.